“The creation of RainDance Technologies France SARL enhances our company’s ability to collaborate with leading European institutions engaged in drug discovery, genomics, and molecular biology research,” said Chris McNary, President and Chief Executive Officer, RainDance Technologies. “In addition, it will position our proven droplet-based technology for new business opportunities as we expand our presence in the growing European market. RainDance Technologies’ speed and simplicity will enable biomedical researchers to design experiments in ways that were previously unaffordable or unthinkable.”
To house its new subsidiary, RainDance has leased facilities at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS), Université Louis Pasteur, in Strasbourg.
“Locating our offices at ISIS will continue our close relationship with Dr. Andrew Griffiths, a RainDance founder and the Director of the ISIS Chemical Biology Laboratory,” said McNary. “Dr. Griffiths is renowned for his work in the development of phage display for the selection of human antibodies for therapy, and for the development of a novel technique for selection and directed evolution of both nucleic acids and proteins. His support and guidance will be significant assets as we identify and engage in new research partnerships,” he said.
About RainDance Technologies, Inc.
RainDance Technologies is a provider of innovative droplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology enable researchers to design experiments in ways that were previously unaffordable or unimaginable.
The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt highly referenced assays for high-speed workflows with minimized process-induced bias or error.
RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.
RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England; and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board. RainDance advisers include three Nobel Prize winners: Jean-Marie Lehn (Chemistry, 1987), Aaron Klug (Chemistry, 2002), and Sir Richard Roberts (Physiology or Medicine, 1993), as well as Sir Gregory Winter, joint head of the British Division of Protein and Nucleic Acids Chemistry at the Medical Research Council's Laboratory of Molecular Biology in Cambridge.
For more information, please visit www.raindancetechnologies.com.
Contact: For corporate questions, contact: RainDance Technologies Steve Becker, 781-861-6300 beckers@raindancetechnologies.com or For technical questions, contact: RainDance Technologies Jeremy Lambert, 781-861-6300 lambertj@raindancetechnologies.com
Source: RainDance Technologies, Inc.
